These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 3534742)

  • 41. [Aminophenazone half life in patients with chronic liver parenchyma disorders].
    Ackermann E; Renger F; Dökert B; Walther M
    Z Gesamte Inn Med; 1972 Oct; 27(19):849-53. PubMed ID: 4647370
    [No Abstract]   [Full Text] [Related]  

  • 42. Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment.
    Baumgartner JD; Glauser MP
    Arch Intern Med; 1983 Oct; 143(10):1868-73. PubMed ID: 6312914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
    Karthaus M; Südhoff T; Fenchel K; Egerer G; Kämpfe D; Ritter J; Franke A; Heil G; Peters G; Jürgens H
    Wien Med Wochenschr; 1998; 148(21):481-7. PubMed ID: 10048176
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ceftriaxone pharmacokinetics during cardiopulmonary bypass.
    Oksenhendler G; Leroy A; Schleifer D; Hubscher C; Soyer R
    Chemioterapia; 1987 Jun; 6(2 Suppl):271-2. PubMed ID: 3509410
    [No Abstract]   [Full Text] [Related]  

  • 45. Terminal half-lives of drugs studied in patients with hepatic diseases.
    Closson RG
    Am J Hosp Pharm; 1977 May; 34(5):520-4. PubMed ID: 326043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic implications of impaired hepatic oxygen diffusion in chronic liver disease.
    Morgan DJ; McLean AJ
    Hepatology; 1991 Dec; 14(6):1280-2. PubMed ID: 1959879
    [No Abstract]   [Full Text] [Related]  

  • 47. Penetration of ceftriaxone into human pleural fluid.
    Benoni G; Arosio E; Cuzzolin L; Vaona B; Raimondi MG; Lechi A
    Antimicrob Agents Chemother; 1986 May; 29(5):906-8. PubMed ID: 3729347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effects of liver disease on pharmacokinetics of drugs and its therapeutic implications].
    Nunes AM
    Rev Port Cardiol; 1992 Feb; 11(2):177-84. PubMed ID: 1567639
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacokinetics of ceftriaxone in serum and gynecological tissues.
    De Grandi P; Bauen JF
    Chemotherapy; 1986; 32(6):473-7. PubMed ID: 3802952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ceftriaxone pharmacokinetics during continuous arteriovenous haemofiltration.
    de'Clari F
    J Antimicrob Chemother; 1991 Mar; 27(3):394-6. PubMed ID: 2037545
    [No Abstract]   [Full Text] [Related]  

  • 51. [The risk of drug overdosage in hepatic diseases].
    Bircher J
    Acta Gastroenterol Belg; 1988; 51(1):102-5. PubMed ID: 3188815
    [No Abstract]   [Full Text] [Related]  

  • 52. Cholestatic hepatitis with intravenous ceftriaxone.
    Kaur I; Singh J
    Indian J Pharmacol; 2011 Jul; 43(4):474-5. PubMed ID: 21845011
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inactivation of ceftriaxone by faecal enzyme preparations during ceftriaxone treatment.
    Welling GW; Holtrop A; Slootmaker-van der Meulen C; Meijer-Severs GJ; van Santen E; Tonk RH; de Vries-Hospers HG; van der Waaij D
    J Antimicrob Chemother; 1992 Aug; 30(2):234-6. PubMed ID: 1399936
    [No Abstract]   [Full Text] [Related]  

  • 54. [Comparison of the diffusion of ceftriaxone in digestive surgery after a single administration at doses of one and two grams].
    Lokiec F; Boudinet A; Petot P
    Pathol Biol (Paris); 1987 May; 35(5):448-50. PubMed ID: 3302845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of ceftriaxone in serum and in gynecological tissues.
    Götz A; Weissenbacher ER; Gutschow K; Wachter I; Schneider A
    Acta Eur Fertil; 1987; 18(2):127-8. PubMed ID: 3630575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Pharmacokinetics and tissue penetration of ceftriaxone].
    Bergan T
    Rev Med Interne; 1985 Mar; 6(2):163-77. PubMed ID: 3890053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Hepatic diffusion of ceftriaxone].
    Lucht F; Tigaud S; Brun M; Mahul P; Peyramond D; Bertrand JL
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):559-60. PubMed ID: 3534742
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections.
    Joos B; Luethy R; Muehlen E; Siegenthaler W
    Am J Med; 1984 Oct; 77(4C):59-62. PubMed ID: 6093521
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.